Hiroaki Ozasa

Kyoto, 6068507, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Correction: Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Correction: Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Journal: Cancer research

Published: June 26, 2026

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 18, 2025

Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation.

Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8+ T cell responses and promoting tertiary lymphoid structure formation.

Journal: Nature communications

Published: September 17, 2025

Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells.

Journal: Cancer research

Published: August 04, 2025

Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.

Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.

Journal: Nature communications

Published: July 10, 2025

Deuterosomal cells are the responsible lineage for multiciliogenesis in human airway differentiation.

Deuterosomal cells are the responsible lineage for multiciliogenesis in human airway differentiation.

Journal: Stem cell reports

Published: June 20, 2025

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study.

The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors depends on the tumor proportion score: a retrospective study.

Journal: Journal of cancer research and clinical oncology

Published: November 20, 2024

Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer.

Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer.

Journal: Molecular and clinical oncology

Published: November 20, 2024

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.

Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.

Journal: Cancer science

Published: November 14, 2024

ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis.

ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis.

Journal: JCI insight

Published: September 16, 2024

Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.

Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study.

Journal: BMC cancer

Published: July 05, 2024

Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer.

Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer.

Journal: Journal of thoracic disease

Published: May 30, 2024

Showing 1-12 of 76

Last Updated: 09/26/2026